Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Peter F. M. Wrigley"'
Publikováno v:
Scandinavian Journal of Haematology. 16:258-262
24 patients with Philadelphia chromosome positive chronic myeloid leukaemia (CML) in blast crisis were treated with intensive chemotherapy. 16 patients showed either partial or complete response to this treatment, but median survival remained short (
Autor:
J. A. L. Amess, M. A. Horton, T. A. Lister, E. Dorey, Peter F. M. Wrigley, A. M. Oza, A. Z. S. Rohatiner, M. Leahy, C. L. Davis
Publikováno v:
Hematological Oncology. 9:337-347
Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vin
Publikováno v:
British Journal of Cancer
Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primary, and three with advanced neuroendocrine tumours, were entered into a study of bolus plus infusional 5-fluorouracil (FUra) modulated with high-dose leucovorin (LV) and re
Autor:
Walter M Gregory, J. A. L. Amess, L. Dadiotis, V. Barbounis, T. A. Lister, Peter F. M. Wrigley, A. M. Oza, J. Lim, A. G. Stansfeld, Arthur Jones, Trivadi S. Ganesan, M. Leahy, A. Z. S. Rohatiner
Publikováno v:
Annals of Oncology. 4:385-392
BACKGROUND Prolonged remission can now be induced in the majority of patients with Hodgkin's disease with chemotherapy and/or irradiation. However, there is a significant proportion of patients in whom this approach fails, either at presentation or s
Autor:
M. Butcher, Peter F. M. Wrigley, Peter Johnson, S. Love, S. P. Joel, L. Squires, M. L. Slevin, M. R. Pandian
Publikováno v:
British Journal of Cancer
Levels of the tumour markers neurone specific enolase (NSE), lactate dehydrogenase (LDH), chromogranin A (ChrA) and carcinoembryonic antigen (CEA) were measured in serum taken at presentation and during treatment, remission and relapse from 154 patie
Autor:
W. S. Shand, T. A. Lister, S. Arnott, N. Perry, Peter F. M. Wrigley, Trivadi S. Ganesan, J. D'Ardenne, A. M. Oza, A. G. Stansfeld
Publikováno v:
Annals of Oncology. 3:349-356
One hundred seventy-seven consecutive patients with newly diagnosed stage II Hodgkin's disease (HD) (supradragmatic 157; infra diaphragmatic 20) were treated at St. Bartholomew's Hospital on the basis of pathologic stage (PS) in 84 (IIA 69; IIB 15) a
Autor:
Trivadi S. Ganesan, T. A. Lister, W. S. Shand, A. J. D'ardenne, Peter F. M. Wrigley, P. A. Murray, A. G. Stansfeld, Arthur Jones, J. S. Malpas, S. Arnott
Publikováno v:
British Journal of Cancer
One hundred and one consecutive patients with newly diagnosed stage I Hodgkin's disease (HD) received treatment at St Bartholomew's Hospital, between 1968 and 1987, with a median follow-up of 12 years. Eleven patients have been excluded from detailed
Autor:
Maurice L. Slevin, Paul Turner, Mark J. Caulfield, S. M. L. Abrams, Peter F. M. Wrigley, Mary Lawson, W. M. Heybroek, R. Raveendran
Publikováno v:
Human & Experimental Toxicology. 11:291-293
Indomethacin, a non-steroidal anti-inflammatory drug is known to increase the efficacy and toxicity of methotrexate, the widely used anti-cancer drug in man. The mechanism for this interaction has not been clearly established. However, since these dr
Autor:
D C Talbot, R. Osborne, Maurice L. Slevin, Rodney H. Reznek, P. I. Clarke, Peter F. M. Wrigley, S. T. A. Malik
Publikováno v:
British Journal of Cancer
A phase II trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with
Autor:
Peter F. M. Wrigley, Rodney H. Reznek, P I Clark, D. I. Talbot, Peter Johnson, T. Masud, S. P. Joel, R. Osborne, Walter M Gregory, Maurice L. Slevin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(7)
PURPOSE Etoposide is a schedule-dependent drug, as demonstrated by the superiority of 5 consecutive daily infusions over a continuous 24-hour infusion in patients with small-cell lung cancer. A randomized trial has therefore been conducted to compare